Table 3 Serum bactericidal antibody (SBA) titres from serum samples obtained before and after the introduction of the MenC conjugate vaccine [9]
Age | Pre-introduction MenC vaccine (1995/6) | Post-introduction MenC vaccine (2006/7) | ||||
|---|---|---|---|---|---|---|
|  | No. samples | SBA-GMT (95% CI) | % samples SBA ≥ 8 | No. samples | SBA-GMT (95% CI) | % samples SBA ≥ 8 |
0-7 mths | 3 | 2 (NA) | 0 | 59 | 2 (n.a.) | 0 |
8-14 mths | 13 | 2.1 (1.9-2.4) | 0 | 62 | 2.4 (1.9-3.0) | 3.2 |
15-24 mths | 18 | 2.0 (NA) | 0 | 27 | 131.3 (64.5-267.5) | 92.6 |
2 yrs | 24 | 2.0 (NA) | 0 | 42 | 13.1 (8.3-20.8) | 61.9 |
3-4 yrs | 42 | 2.1 (1.9-2.4) | 2.6 | 106 | 5.4 (3.8-7.7) | 30.2 |
5-6 yrs | 34 | 2.8 (1.6-4.7) | 6 | 49 | 5.2 (3.4-7.8) | 28.6 |
7-8 yrs | 43 | 3.4 (2.2-5.2) | 11.2 | 56 | 5.1 (3.7-7.1) | 33.9 |
9-10 yrsa | 27 | 3.0 (1.3-6.9) | 11.3 | 73 | 9.4 (5.8-15.2) | 45.2 |
11-12 yrs | 31 | 2.5 (1.4-4.5) | 8.4 | 72 | 20.0 (12.4-32.2) | 61.1 |
13-14 yrs | 34 | 5.6 (2.1-14.8) | 23.5 | 65 | 23.5 (15.9-34.6) | 69.2 |
15-16 yrs | 38 | 3.3 (2.1-5.1) | 16.3 | 55 | 57.9 (36.7-91.1) | 81.8 |
17-18 yrs | 25 | 3.6 (1.8-7.1) | 11.7 | 43 | 89.8 (58.4-138.0) | 86 |
19-21 yrs | 21 | 2.6 (1.9-3.5) | 5.9 | 88 | 159.6 (109.1-233.4) | 95.5 |
22-25 yrs | 38 | 6.2 (3.1-12.4) | 26.1 | 104 | 4.2 (9.1-22.6) | 49 |
26-30 yrs | 56 | 4.6 (2.1-10.0) | 24.5 | 69 | 4.2 (3.1-5.9) | 26.1 |
31-39 yrs | 66 | 4.7 (3.8-5.8) | 22.5 | 58 | 3.6 (2.1-6.0) | 19 |
40-49 yrs | 65 | 5.3 (4.0-6.9) | 26 | 49 | 4.1 (2.5-6.7) | 20.4 |
50-59 yrs | 59 | 4.5 (3.9-5.2) | 19.2 | 52 | 4.1 (2.5-6.6) | 21.2 |
60-69 yrs | 51 | 5.9 (3.0-11.5) | 29.5 | 54 | 3.2 (2.7-3.7) | 18.5 |
70-79 yrs | 48 | 3.6 (2.1-6.1) | 17.1 | 37 | 3.6 (2.5-5.4) | 21.6 |
Total | 736 | 4.3 (3.3-5.5) | 19.7 | 1220 | 10.2 (8.9-11.7) | 43.0 |